Notably, we identified silibinin as a promising therapeutic agent that inhibits the FAT10-NCOA4 axis, effectively reducing both inflammation and ferroptosis in models of AP (Fig. 7). Here, NCOA4 is linked to alkaline phosphatase measurement.